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The ﬁrst case that led researchers to put forward a new concept of autoimmune pancreatitis (AIP) was treated with steroids by
gastroenterologists in Tokyo Women’s Medical University. It is important to diﬀerentiate AIP from pancreatic cancer before treat-
ment with steroids is started. Today, steroids are standard therapy for AIP worldwide. In the Japanese consensus guidelines, steroid
therapy is indicated for symptomatic AIP. After management of glucose levels and obstructive jaundice, oral prednisolone is
initiated at 0.6mg/kg/day for 2–4 weeks and is gradually tapered to a maintenance dose of 2.5–5mg/day over 2-3 months. To pre-
vent relapse, maintenance therapy with low-dose prednisolone is used. For relapsed AIP, readministration or increased doses of
steroidsareeﬀective.ThepresenceofproximalbileductstenosisandelevatedserumIgG4levelsmaybepredictiveofrelapseofAIP.
It is necessary to verify the validity of the Japanese regimen of steroid therapy for AIP. The necessity, drugs, and duration of main-
tenance therapy for AIP need to be clariﬁed by prospective studies.
1.Introduction
The ﬁrst case that led researchers to put forward a new
concept of autoimmune pancreatitis (AIP) was treated with
steroids by gastroenterologists (Professor Tadashi Takeuchi)
in Tokyo Women’s Medical University, and the concept was
proposed by Yoshida, a member of the group, in 1995 [1].
This paper describes the anecdotes of treatment of the ﬁrst
case that led researchers to put forward a new concept of AIP
and reviews current strategies for treatment of this disorder.
2. Anecdotes of Treatmentof the FirstAIP Case
In 1993, a 68-year-old woman who had undergone exp-
loratory laparotomy for jaundice and an abdominal tumor
atanotherhospital,butshewasfoundtohaveadvancedpan-
creaticcancerthatwasinoperable,andonemonthafterbeing
discharged she came to Tokyo Women’s Medical University
Hospital to be treated for pancreatic cancer.
Her general condition was good, and during that 1-
month period her jaundice had spontaneously improved
without any treatment. Based on the physical examination,
the laboratory results, and the ﬁndings obtained by diagnos-
tic imaging, AIP would come to mind today, but there was
no concept of AIP in those days.
As far as steroid therapy is concerned, we have to pay
attention to side eﬀects or complications such as steroid-in-
duced pancreatitis. However, it was fortunate that steroid
therapy was dramatically eﬀective without any side eﬀects in
this patient; her physical ﬁndings, laboratory data, and diag-
nostic imaging ﬁndings became normal, and she was dis-
charged uneventfully.
The 8-week steroid therapy was eﬀective, with the results
that hyperglobulinemia and positive autoantibody were nor-
malized, and swelling of the pancreas and irregular narrow-
ing of the main pancreatic duct were also normalized. Those
were clearly attributable to an autoimmune mechanism, and
we proposed autoimmune pancreatitis.2 International Journal of Rheumatology
By the way, the case report was submitted to Digestive
Diseases and Sciences in the summer of 1993 [1], and it had
taken about two years since it had originally been submitted.
There was a comment by a reviewer that since it was just
a report of a single case, adding the subtitle “Proposal of
the Concept of Autoimmune Pancreatitis” may have been an
overstatement or an exaggeration. However, retaining the
subtitle made a considerable impact, and it might have
attracted a great deal attention in the age of the Internet.
Obviously, it is diﬃcult to propose anything new.
3. Treatment of AIP
AIPhasrecentlybeensubclassiﬁedintotype1andtype2AIP
[2, 3]. Type 1 AIP is a classical AIP that shows a histology of
lymphoplasmacytic sclerosing pancreatitis and is considered
thepancreaticmanifestationofIgG4-relatedsystemicdisease
[4, 5]. Type 2 AIP shows a histology of idiopathic duct-
centric chronic pancreatitis and is not related to IgG4 [2, 3].
Although it is reported that type 2 AIP responds well to
steroid therapy, similar to type 1 AIP [2], the precise clinical
featuresoftype2AIPhavenotbeenclariﬁed.Onlytreatment
of type 1 AIP is described in this paper.
3.1. Spontaneous Improvement. In some AIP patients, imp-
rovement of swelling of the pancreas or irregular narrowing
ofthemainpancreaticductimproveswithoutsteroidtherapy
[6–8]. In our series [6] ,3o f1 2A I Pp a t i e n t sw h ow e r ef o l -
lowed for more than 6 months without steroid therapy im-
proved spontaneously, but 2 of them received steroid therapy
later. Wakabayashi et al. [7] reported on 4 AIP patients who
showed spontaneous regression; they had negative immu-
noserological tests and no biliary lesions. Kubota et al. [8]
reported that seronegative ﬁndings for IgG4, no obstructive
jaundice, and focal swelling of the pancreas were related to
spontaneous remission. Considering that patients who are
later treated with steroids due to AIP exacerbation also show
steroid responsiveness, asymptomatic segmental AIP cases
without biliary lesions may be followed without steroid
therapy with periodic laboratory and imaging tests.
3.2. Indication. Because the ﬁbroinﬂammatory process in
AIP responds well to steroid therapy, administration of oral
steroids has become standard therapy for AIP. However, it is
important to diﬀerentiate pancreatic cancer from AIP before
startingtreatmentwithsteroidsinAIPpatients.Accordingto
a recent international study of AIP [9], steroids are used for
AIP patients in all countries. In the Japanese consensus
guidelines for the management of AIP [10], indications for
steroid therapy in AIP include symptoms such as obstructive
jaundice due to associated sclerosing cholangitis and the pre-
sence of symptomatic extrapancreatic lesions such as hydro-
nephrosis due to retroperitoneal ﬁbrosis. Because diabetes
mellitus (DM) seen in the acute presentation of AIP some-
times improves with steroid therapy, DM coincidental with
AIP might be an indication for steroid therapy [10]. Al-
thoughimprovementinclinicalﬁndingswithsteroidtherapy
may be useful in the diﬀerential diagnosis of AIP from
pancreatic cancer, facile diagnostic steroid trial should be
avoided not to misdiagnose pancreatic cancer as AIP. Diag-
nostic steroid trials should be conducted carefully by pancre-
atologists only after a negative workup for cancer including
endoscopic ultrasound-guided ﬁne needle aspiration [11,
12]. Serological and imaging tests should be done 2 weeks
after commencement of steroid therapy. Rapid response to
steroids is reassuring and conﬁrms the diagnosis of AIP. If
steroid eﬀectiveness is reduced, the patient should be reeva-
luated on suspicion of pancreatic cancer.
3.3. Steroid Regimen. In the Japanese guidelines [10], before
starting steroid therapy, biliary drainage is usually done in
cases with obstructive jaundice. However, as there are some
patients whose jaundice is relieved by steroid therapy alone,
it is unclear if biliary obstruction can be treated with steroid
therapy alone without biliary drainage [13]. In cases with
DM, glucose levels must be controlled. The recommended
initial oral prednisolone dose is 0.6mg/kg/day. Serological
and imaging tests should be done periodically after com-
mencement of steroid therapy [10]. Magnetic resonance
cholangiopancreatography is useful to observe the response
tosteroidsinthepancreaticobiliaryductsnoninvasively[14].
Pancreatic size usually normalizes within a few weeks, and
biliarydrainagebecomesunnecessarywithinabout1month.
Rapid response to steroids is reassuring and conﬁrms the
diagnosis of AIP. If steroid eﬀectiveness is reduced, the
patient should be reevaluated with a suspicion of pancreatic
cancer. The initial dose of steroids should be administered
for 2–4 weeks, and the dose should be gradually tapered to
a maintenance dose of 2.5–5mg/day over 2-3 months [10]
(Figure 1).
In the Mayo Clinic [15], prednisolone is used at 40mg/
day for 4 weeks and is tapered by 5mg/week for a total of 11
weeks of therapy. In Korea [16], remission is achieved on a
regimen of prednisolone 0.5mg/kg per day for 1-2 months
followed by a gradual tapering of 5–10mg per month to a
maintenance dose of 2.5–7.5mg/day.
3.4. Remission. Remission is deﬁned as the disappearance of
clinical symptoms and resolution of the pancreatic and/or
extrapancreatic manifestations on imaging studies [17].
In a multicenter survey of steroid therapy for AIP [17],
at remission, the enlarged pancreas returned to near-normal
size in 239 of 300 patients (80%) and became atrophic in 58
patients (20%). Elevated serum IgG4 levels decreased in all
patients after the start of steroid therapy but failed to nor-
malize (<135mg/dL) in 115 of 182 patients (63%). At remis-
sion, irregularity of the pancreatic ducts and/or some degree
of bile duct stenosis remained in 67 of 115 patients (58%)
with persistent elevation of serum IgG4 levels, but only 18 of
67 patients (27%) with normalized serum IgG4 levels.
I no u ro t h e rs t u d y[ 18], HbA1c decreased by more than
0.5% in 8 of 21 AIP patients (38%) with DM after 3 months
of steroid therapy. One year after the start of therapy, HbA1c
decreased compared with levels before steroid therapy in
13 of 15 DM patients (87%). Impaired pancreatic exocrine
function improved in all AIP patients and normalized in half
of them [19].International Journal of Rheumatology 3
Regimen of steroid therapy for AIP
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Figure 1: Regimen of oral steroid therapy for AIP.
3.5. Relapse and Maintenance Therapy. Relapse of AIP is de-
ﬁned as reappearance of symptoms with the reappearance of
pancreatic and/or extrapancreatic (including bile duct, sali-
vary gland, and retroperitoneum) abnormalities on imaging
and/or elevation of serum IgG4 levels [17].
In a multicenter survey [17], the relapse rate of AIP pa-
tients was signiﬁcantly lower in those who received steroid
therapy (24%, 110/451) than in those not given steroid
therapy (42%, 32/77). There was no correlation between the
relapse rate and the initial prednisolone dose (40mg/day,
19% (31/160) versus 30mg/day, 23% (65/283)). In patients
who received steroid therapy, relapse occurred in the pan-
creas (n = 57, 52%), bile duct (n = 37, 34%), and extra-
pancreatic lesions (n = 19; salivary gland swelling (n = 10),
interstitial pneumonia (n = 4), and others (n = 5)).
Maintenance steroid therapy (oral prednisolone dose:
2.5mg–5mg/day) was given after remission in 377 of 459
patients (82%) treated with steroids. The relapse rate with
maintenance therapy was 23% (63/273), which was signiﬁ-
cantly lower than that of patients who stopped maintenance
therapy (34%, 35/104) [17]. In the United States and United
Kingdom, where no maintenance therapy was given, relapse
rates of patients treated with steroids were reportedly 38–
60% [20–22]. In Korea, where maintenance therapy was
stopped completely after about 6 months, the relapse rate
of AIP patients treated with steroids was 33% (13/40) [16].
In consideration of these ﬁndings, maintenance therapy with
low-dose prednisolone may prevent relapse. In Japan, main-
tenance therapy is used for about 1–3 years. However, the
optimal duration of maintenance therapy is an issue requir-
ing further investigation, as continued steroid therapy may
increase the risk of steroid-induced adverse events. AIP often
occurs in the elderly, who are already at heightened risk for
osteoporosis and complications of glucose intolerance.
For relapsed AIP, readministration or increasing the dose
of steroids is eﬀective. In the United States and United
Kingdom, immunomodulatory drugs such as azathioprine
were used for maintenance of remission in patients with
relapse after steroid withdrawal although azathioprine also
has adverse eﬀects such as allergic reactions, bone marrow
suppression, and increased risk of infection [20–22]. Re-
cently, it was reported that an AIP patient refractory to
steroids and 6 mercaptopurine was successfully treated with
rituximab, a monoclonal antibody directed against the CD20
a n t i g e no nBl y m p h o c y t e s[ 23].
3.6. Predictive Factors for Relapse. For patients with relapsed
AIP, maintenance therapy with steroids should be given with
longerdurationandhigherdosethanthatoftheinitialmain-
tenance therapy. Furthermore, pancreatic stones may form
in some relapsing AIP patients, which might be induced by
pancreatic juice stasis from incomplete obstruction of an
irreversibly damaged pancreatic duct system [24]. Therefore,
relapse of AIP should be avoided as much as possible. Iden-
tiﬁcation of risk factors for relapse may help to identify high-
risk patients who would beneﬁt from maintenance therapy
up front, and allow short-term therapy in lower-risk patients
who may not need long-term therapy.
Hirano et al. [25] reported that obstructive jaundice is
a predictive factor for unfavorable events. Kubota et al. [8]
reported that diﬀuse pancreatic swelling independently
predicted a relapse of AIP. Raina et al. described that relapse
occurredin7of9patients(78%)withextrapancreaticbiliary
stenosis after withdrawal of immunosuppressive therapy
[21]. Ghazale et al. reported that the relapse rate (64%) of
patients with proximal biliary stenosis was signiﬁcantly
higher than that of patients with distal biliary stenosis alone
(32%) [22]. In Korean data, relapse rate in patients with
intrahepatic or proximal biliary stenosis was 65% compared
with 25% in those without proximal biliary disease [26]. In
a multicenter study [17], the relapse rate of AIP was signif-
icantly higher in patients with persistent elevation of serum
IgG4 levels (30%, 34/115) than in those with normalized
serum IgG4 levels (10%, 7/69). Although serum IgG4 levels
ﬂuctuated by more than 30mg/dL in 94 of 172 patients
(55%) during maintenance therapy, reelevation of serum
IgG4 levels was detected in 37 of 54 patients (69%) who
relapsed during maintenance therapy. The presence of proxi-
mal bile duct stenosis and elevated serum IgG4 levels may be
predictive factors of relapse of AIP. Changes in serum IgG4
levels during serial checkups may provide clinically useful
information to detect relapse of AIP earlier.
In the future, it will be necessary to verify the validity of
the Japanese regimen of steroid therapy for AIP. The neces-
sity, drugs, and duration of maintenance therapy need to be
clariﬁed by prospective studies.
As recent interesting reports have shown that pancreatic
cancer was complicated with AIP [27, 28], we have to pay
attention not only AIP but also pancreatic cancer even in a
follow-up period.
4. Conclusion
It is important to diﬀerentiate AIP from pancreatic cancer
before starting therapy. Steroids are the standard therapy for
AIP, but this regimen should be evaluated in prospective
studies.4 International Journal of Rheumatology
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